Oncobesity News Posts

Novo Nordisk executive reports high interest for once-daily, oral weight-loss pill
Wegovy’s oral version of its injectable weight-loss drug is seeing tremendous interest, Novo Nordisk executive Dave Moore told FOX Business on Friday. Wegovy’s once-daily pill,

The launch of the world’s first weight-loss pill
Bad news for all those who have been trying to make “Jabuary” a thing, said Angus Colwell in The Spectator. The launch of the world’s

Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists
This review talks about the development of incretin agonists (glucagon-like peptide-1 [GLP-1], GIP [glucose-dependent insulinotropic polypeptide], glucagon), oral formulation development approaches, and advanced drug delivery

Ongoing lymphoid HIV production drives pyroptosis and GLP-1 counter-regulation in ART-suppressed infection
Despite effective antiretroviral therapy (ART), many people with HIV (PWH) exhibit persistent immune activation (IA) and suffer metabolic comorbidities. We investigated whether residual HIV production

Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best performing pharma stocks in 2025. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced on January 8 the selection of

The clock starts ticking the day you quit your GLP‑1 medication – Scripps News
The clock starts ticking the day you quit your GLP‑1 medication Scripps News People coming off weight-loss injections risk fast weight gain BBC Many people who come

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval

The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth
Quick Read Lilly posted 53.9% revenue growth and 480% net income growth driven by GLP-1 drugs Mounjaro and Zepbound. Lilly’s operating margin hit 48.3% versus

People Who Go Off GLP-1s Are Experiencing a Sudden and Terrible Hunger
Glucagon-like peptide-1 (GLP-1) receptor agonist drugs, like the popular weight-loss jabs Wegovy and Ozempic, have proven to be immensely effective. Beyond allowing patients to significantly

Medicina, Vol. 62, Pages 143: GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study
Medicina, Vol. 62, Pages 143: GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study Medicina

Gut-derived GLP-1 released by rare sugar D-allulose cooperates with insulin to activate left-sided vagal afferents and enhance insulin sensitivity
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) ameliorate hyperglycemia by directly stimulating insulin secretion from the pancreas. In contrast, the physiological role of short-lived endogenous GLP-1 remains

Doctors urge caution as study finds rapid weight regain after weight-loss drugs
A study found people who stopped GLP-1 weight-loss drugs such as Ozempic, regained weight rapidly and faced higher risks of diabetes, high cholesterol and high

Wegovy just became available in an unexpected place
Days after hitting the market, the new pill version of Novo Nordisk’s wildly popular weight-loss drug will be available through Amazon’s online pharmacy. Amazon joins

Amazon Pharmacy Disrupts Weight Loss Market with Oral Wegovy: $149 Cash-Pay Option and Same-Day Delivery
What You Should Know – Amazon Pharmacy has officially added Novo Nordisk’s Wegovy® pill—the first and only FDA-approved oral GLP-1 for weight management—to its nationwide

I’m a Dietitian Taking A GLP-1. These Are My Go-To Simple Meals
These medications changed not only my appetite, but the entire way I think about food, hunger, and self-care.

Study reveals how fast weight returns after ending GLP-1 drugs
Post Content

Novo Nordisk Gets Discounted as Investors Look Past the Next Phase of GLP-1 Growth

George Mason trial: New pill aims to sustain weight loss after GLP-1s
GLP-1 medications like Ozempic and Wegovy have transformed obesity treatment, but maintaining weight loss after the medications stop remains a challenge.

Joel Habener, Whose Research Led to Weight-Loss Drugs, Dies at 88
His discovery of the protein fragment GLP-1 was crucial in the development of Ozempic, Wegovy and other blockbuster obesity and diabetes treatments.

You’re Doing This Right — And Still Not Burning Fat | Dr. Mandell
Many people eat healthy, cut sugar, and still struggle with stubborn fat, low energy, or blood sugar swings. In this video, Dr. Mandell explains why

Novo Nordisk’s (NVO)
Novo Nordisk’s (NVO) Novo Nordisk A/S Sponsored ADR Class B BATS:NVO KalaGhazi Based on a detailed technical analysis of Novo Nordisk’s (NVO) stock in the

J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
Johnson & Johnson JNJ recently signed a landmark agreement with the Trump administration to lower drug prices in the United States. Following this deal, JNJ joins

Amylyx selects AMX-0318 as development candidate
Amylyx Pharmaceuticals Inc. has nominated AMX-0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia and other rare diseases.

Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond
2025 was a tumultuous year for the global healthcare sector. For much of the year, policy uncertainty, particularly around U.S. drug pricing and trade barriers,

THE WORLD IS FLAT FAT: More than a quarter of adults worldwide could benefit from GLP-1 medications
THE WORLD IS FLAT FAT: More than a quarter of adults worldwide could benefit from GLP-1 medications for weight loss, study finds.

Mounjaro: Experts issue warning over black market jabs, with fifth of areas still lacking NHS access
One in five local areas in England still do not provide the weight loss jab tirzepatide (Mounjaro) on the NHS six months after the drug

Is Giving ChatGPT Health Your Medical Records a Good Idea?
Your AI doctor’s office is expanding. On Jan. 7, OpenAI announced that over the coming weeks, it will roll out ChatGPT Health, a dedicated tab

Nightline Full Broadcast – Thursday, January 8, 2026
01:34 – GLP-1 drugs may be helpful for addiction recovery 11:23 – Lucy Liu on her latest role 18:28 – The return of Star Search

Drug approvals to watch in 2026
Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with

VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug
Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of VK2735, the company’s dual agonist of the GLP-1 and

Here’s Why Biotech ETFs Are Rallying Hard
Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions.

Surgery Beats GLP-1 Drugs for Fat Loss, Muscle Retention, Study Suggests
(MedPage Today) — Bariatric surgery and GLP-1 receptor agonists both reduced fat mass over 2 years of treatment, but surgery was associated with a more

Weight loss drugs make it harder to get the nutrients you need – here’s what to do about it
Weight-loss drugs such as Ozempic, Wegovy and Mounjaro work primarily by reducing hunger. They mimic a hormone the body already produces called glucagon-like peptide-1 (GLP-1),

GLP-1 Drugs May Protect Against Vertebral Fractures
Glucagon-like peptide-1 (GLP-1) receptor agonists were associated with a lower vertebral fracture risk in patients with type 2 diabetes, according to a study published in

6 Takeaways from the WHO’s First Obesity Drug Guideline
This Medical News article discusses key learnings from new World Health Organization guidance on the use of glucagon-like peptide-1 (GLP-1) medications for the treatment of

Weight Often Returns After Stopping Ozempic, Wegovy, Study Finds
FRIDAY, Jan. 9, 2026 — People who stop taking popular weight loss drugs like Ozempic and Wegovy are likely to gain the weight back, and sooner than many expect, a new study finds.
Researchers reviewed dozens of earlier studies and found that…

Nutritional Guidance Lacking for Adults Receiving Semaglutide, Tirzepatide
FRIDAY, Jan. 9, 2026 — Nutritional guidance to support safe weight loss is frequently lacking for adults with obesity or type 2 diabetes receiving semaglutide or tirzepatide, according to a study published online Jan. 8 in Obesity Reviews.
Marie…

The Simply Good Foods Company (NASDAQ:SMPL) Q1 2026 Earnings Call Transcript
The Simply Good Foods Company (NASDAQ:SMPL) Q1 2026 Earnings Call Transcript January 8, 2026 The Simply Good Foods Company beats earnings expectations. Reported EPS is

Prescryptive and Ilant Health Expand Employer-Direct Access to Obesity Care and Transparent GLP-1 Access at Scale
REDMOND, Wash., Jan. 9, 2026 /PRNewswire/ — Prescryptive and Ilant Health today announced a collaboration to help employers access transparent GLP-1 pricing alongside expert, outcomes-driven

Amazon Pharmacy Expands Access to New Wegovy® Pill with Insurance and Cash-Pay Options
SEATTLE–(BUSINESS WIRE)–Amazon Pharmacy now offers Novo Nordisk’s newly FDA-approved oral GLP-1 with transparent pricing and fast, free home delivery